Possible scenario
AI Biotech Read-Through
20% Chance
The successful listing is interpreted as evidence that public investors remain open to AI-enabled drug discovery platforms. The strongest effects remain in directly comparable public companies, while sector-wide market effects are negligible.
Tickers
- RXRX+1.9%
- SDGR+1.6%
Portfolio impact
S&P 5000.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.